Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for North Carolina Only)
Policy governing coverage of multiplex nucleic acid (PCR) gastrointestinal pathogen panel testing for evaluation of infectious diarrhea for UnitedHealthcare Community Plan members in North Carolina.
CPT code 0369U was added to the applicable codes list.
Testing of gastrointestinal pathogens (11 targets) is unproven and not medically necessary due to insufficient evidence of efficacy.
A notation was added indicating CPT code 0369U is not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by the State of North Carolina Medicaid Program.
Supporting information sections (Description of Services, Clinical Evidence, and References) were updated to reflect current information.
Coverage Criteria
Medically Necessary Indications
Covered when ALL of the following sets of conditions are met:
Supports 3-5 target panels (87505).
Supports 6-11 target panels (87506).
Not Medically Necessary
Not medically necessary / unproven:
Insufficient evidence of efficacy per policy.
Indication-based coverage
Covered when ALL of the following guideline-based clinical indications are met
Testing should follow IDSA/ACG guidance and be limited to circumstances where results may affect management; viral-only panels have limited impact except in immunocompromised hosts.
Parallel culture or confirmatory testing
Additional laboratory requirements for certain pathogens
Evidence shows discordance between NAAT/GPP and culture for Salmonella; enrichment culture may be more sensitive in some studies.
Clinical utility considerations
Clinical utility constraints
Systematic reviews and cohort studies report increased detection but uncertain clinical benefit and potential for false positives leading to unnecessary therapy.
Not Medically Necessary (specific 11-target panel)
Summary coverage statements from this portion of the policy
Declared in Summary of Changes (04/01/2025).
Multiplex nucleic acid amplification tests that include more than 11 targets for gastrointestinal pathogens are explicitly designated as unproven and not medically necessary. The policy states that panels > 11 targets lack sufficient evidence of efficacy and therefore are not covered.
Routine stool testing is not indicated for most cases of uncomplicated, self-limited acute or noninflammatory diarrhea. IDSA and related guidance reserve fecal testing for patients with moderate-to-severe, bloody or febrile diarrhea, persistent diarrhea (>7 days), nosocomial onset, or for immunocompromised individuals. Diagnostic testing is also not routinely recommended for most travelers’ diarrhea unless treatment is indicated or symptoms are prolonged (e.g., parasitic evaluation for diarrhea lasting ≥14 days). Applying guideline-based criteria reduces low-yield testing without substantially affecting clinical yield.
FDA 510(k) clearance or marketing authorization alone is not a basis for coverage. Although several commercial multiplex PCR/NAAT kits (for example, XTAG, FilmArray, Verigene, BioCode) have received FDA clearance, the policy treats clearance as informational and requires evidence of clinical utility and appropriate indications before coverage is supported.
Multiplex PCR panel testing of gastrointestinal pathogens that include > 11 targets is considered unproven and not medically necessary and is not covered. In addition, multiplex panel testing for indications not listed as proven or medically necessary in this policy is also not covered. The policy history reiterates that testing of an 11‑target gastrointestinal panel was specifically reviewed and declared unproven and not medically necessary.
The broad or indiscriminate use of multiplex panels for patients who do not meet guideline-based testing indications (for example, patients without fever, bloody stools, persistent or severe symptoms, or immunocompromise) is considered low-yield. The policy endorses following IDSA/ACG criteria to limit testing to situations where results are likely to affect management; indiscriminate ordering may be deemed not medically necessary.
A gastrointestinal pathogen test described in the policy as an 11‑target panel is explicitly identified as unproven and not medically necessary due to insufficient evidence of efficacy. This determination is included in the Summary of Changes and is reflected in the policy’s not medically necessary statements.
Covered Indications and Clinical Contexts
Diarrhea >7 days
See Medically Necessary Indications for panel-size specifics.
Diarrhea with fever, bloody or mucoid stools, signs of sepsis, severe abdominal cramping/tenderness
Follow guideline-based testing criteria.
Suspected enteric fever with recent travel to endemic region or exposure via food preparer
Enteric fever evaluation should include blood cultures per policy guidance.
Immunocompromised individuals (AIDS, post-transplant, immunosuppressive therapy) with persistent diarrhea
ASM/AST guidance recommends multiplex assays to identify parasites of concern in SOT recipients.
IDSA/ACG-consistent indications
Testing not indicated for most noninflammatory, self-limited acute diarrheas.
Solid organ transplant recipients with suspected GI infection when Cryptosporidium, Cyclospora, or Giardia are concerns
ASM/AST guidance supports multiplex assays in SOT recipients.
Commercial multiplex PCR kits referenced and supporting references listed
FDA clearance alone is not a basis for coverage; presence of cleared kits does not guarantee coverage.
Not Covered / Not Medically Necessary
Multiplex PCR panel testing that includes more than 11 targets and multiplex panel testing for indications not specified as proven or medically necessary in this policy are not covered. The policy’s exclusion for panels > 11 targets applies to UnitedHealthcare Community Plan members in North Carolina.
Use of multiplex panels for routine testing of uncomplicated acute diarrhea or noninflammatory presentations without guideline-based indications is not covered because these scenarios have low clinical yield. The policy specifically notes that following established IDSA/ACG criteria (fever, bloody stool, persistent or severe symptoms, immunocompromise) reduces unnecessary testing while preserving clinical yield.
An 11‑target gastrointestinal pathogen panel is identified in this policy as not covered (not medically necessary) because of insufficient evidence of clinical efficacy. The policy history documents this coverage rationale and also notes the addition of CPT code 0369U to the coding section; providers should be aware that CPT 0369U may not be covered by North Carolina Medicaid as it is not on the State fee schedule.
Coding and Applicable Codes
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA); gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique. |
| 87505 | Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets. |
| 87506 | Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets. |
| 87507 | Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets. |
| FDA 510(k) cleared panels mentioned (XTAG, FilmArray, Verigene, BioCode) — no billing codes provided in this section. |
| 0369U | CPT code 0369U (newly added to policy). |
| FDA 510(k) cleared panels mentioned (XTAG, FilmArray, Verigene, BioCode) — no billing codes provided in this section. |
| 0369U | CPT code 0369U (newly added to policy). |
Provider Actions, Prior Authorization & Documentation
Authorization may be required for listed CPT/PLA codes
Prior authorization may be required for the listed CPT/PLA codes; coverage is limited to the panels and clinical indications specified in this policy. Verify PA requirements with the member's plan before ordering (codes referenced in policy: 87505, 87506, 87507, 0369U).
Guideline-based indication must be documented for PA
When testing is being ordered for presentations that are low yield, prior authorization may be expected and the ordering clinician should document that testing meets guideline-based indications (e.g., fever, bloody diarrhea, immunocompromised status, persistent or severe symptoms).
- Document guideline-based indications per IDSA/ACG (fever, bloody stools, severe abdominal pain, persistent diarrhea, immunocompromise).
CPT 0369U added — check NC Medicaid coverage
CPT code 0369U was added to the policy coding section; note that codes labeled with an asterisk (including 0369U) are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by NC Medicaid—verify prior authorization and state Medicaid coverage before ordering for NC Medicaid members.
- 0369U was added to Applicable Codes in the policy.
- 0369U is not on the State of North Carolina Medicaid Fee Schedule and may not be covered by NC Medicaid.
Prefer targeted or culture-based testing when appropriate
When culture-based or targeted testing is clinically appropriate, clinicians are expected to follow diagnostic algorithms that prioritize targeted or culture methods before broad multiplex panel ordering.
- Use culture-independent methods when indicated by guidelines, but prefer targeted or culture-based testing based on severity, duration, and immunocompetence.
Perform parallel culture/enrichment when indicated
When culture or enrichment methods are required for public health, antimicrobial susceptibility, or confirmatory purposes (for example, Salmonella), culture or enrichment should be performed in parallel or as indicated rather than relying on NAAT alone.
- Enrichment culture for Salmonella may be more sensitive than PCR; perform parallel culture/enrichment when confirmatory or susceptibility testing is needed.
- Positive NAAT results for certain bacterial targets may require confirmatory culture.
Document clinical indication and panel size on the order
Order documentation must include the clinical indication and which panel (target range) was ordered; supporting details should include duration of diarrhea, presence of fever, bloody or mucoid stools, signs of sepsis, severe abdominal cramping/tenderness, travel history for suspected enteric fever, or immunocompromised status.
Document guideline-consistent clinical indications
Documentation must support presence of guideline-consistent clinical indications when ordering multiplex stool NAAT panels (examples: fever, bloody stool, severe abdominal pain, persistent diarrhea >7 days, or immunocompromised status).
- Record specific symptoms (fever, bloody stools, severe cramping) or patient risk factors (immunocompromise, nosocomial onset).
- Follow IDSA/ACG criteria to justify testing.
Verify plan-specific coverage and reference governing benefit language
Coverage decisions must be made in the context of applicable federal, state, or contractual benefit plan language; providers should check plan-specific requirements prior to ordering and reference those requirements when submitting for authorization or coverage.
- In the event of conflict, federal, state, or contractual requirements govern coverage.
- Check plan-specific rules before relying on this policy.
Do not order panels >11 targets — risk of noncoverage
Multiplex PCR panels for gastrointestinal pathogens that include more than 11 targets are considered unproven and not medically necessary and may be denied; do not order >11-target panels for indications not covered by this policy.
- Panels with >11 targets are explicitly listed as unproven/not medically necessary in the policy.
- Ordering such panels risks claim denial as not medically necessary.
Avoid inappropriate or low-yield test ordering
Ordering tests outside recommended clinical indications (for example testing in noninflammatory, self-limited acute diarrhea) is low-yield and may reduce clinical benefit; follow guideline-based ordering to avoid unnecessary testing.
- IDSA/ACG guidance recommends against routine testing for noninflammatory, self-limited diarrhea.
- Applying guideline criteria can reduce unnecessary testing without lowering clinical yield.
Denial risk for tests labeled unproven/not medically necessary
Tests identified in the policy as unproven and not medically necessary—such as the specified 11-target gastrointestinal pathogens panel—may be denied as not medically necessary; expect denial risk for claims for these tests.
- An 11-target gastrointestinal pathogen test is explicitly identified as unproven and not medically necessary in the policy.
- Claims for such tests may be denied on medical necessity grounds.
Ordering Requirements
Order based on clinical presentation; include blood cultures when enteric fever suspected
Orders should be based on clinical presentation including duration and severity of diarrhea and the patient’s immune status; for suspected enteric fever, testing should be performed as part of an appropriate evaluation that includes blood cultures.
- For suspected enteric fever, include travel history and perform blood cultures as part of the evaluation.
- Consider duration (>7 days), presence of fever, bloody stools, or signs of sepsis when deciding to order testing.
Document guideline-based indications; consider specialist ordering
Orderers should document guideline-based clinical indications (for example fever, bloody stools, immunocompromised status); in complex cases, specialist ordering (infectious disease or gastroenterology) may be appropriate or expected.
- Document specific guideline-based reasons for testing.
- Consider specialist involvement for complex or immunocompromised patients.
Follow federal, state, and plan-specific coverage rules before ordering
Providers must follow applicable federal, state, and contractual benefit plan coverage requirements; check plan-specific rules prior to ordering because those requirements govern coverage and may differ from this policy.
- In case of conflict, federal, state, or contractual requirements take precedence.
- Verify PA and coverage rules with the member’s specific plan before ordering.
Frequency Limits
Background
Diarrheal illnesses are caused by bacteria, viruses, protozoa, and parasites; many cases are self-limited. Fecal testing is recommended for presentations that are moderate-to-severe, bloody, febrile, nosocomial, persistent (>7 days), or in immunocompromised patients. Multiplex molecular panels increase detection rates and shorten turnaround time compared with culture, but their clinical impact depends on appropriate patient selection and adherence to guideline-based testing indications.
Definitions
Clinical Evidence and Performance
The policy cites multiple clinical studies, systematic reviews, and professional society guidance to support its position on clinical utility and limitations of multiplex gastrointestinal panels. References include systematic reviews and primary studies showing higher pathogen detection rates with multiplex panels, as well as guidance that FDA clearance alone does not establish clinical utility. The document lists FDA‑cleared kits (e.g., FilmArray, XTAG, Verigene, BioCode) and provides numerous references evaluating performance and clinical impact.
Policy Update Changes & Revision History
Coverage rationale updated: testing of gastrointestinal pathogens (11 targets) declared unproven and not medically necessary due to insufficient evidence of efficacy.
CPT code 0369U added to the Applicable Codes section of the policy.
Notation added that CPT code 0369U is not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by NC Medicaid.
Supporting information (Description of Services, Clinical Evidence, and References) updated to reflect current information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.